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Proximal tubule basolateral membranesWe recently demonstrated that Angiotensin-(3−4) [Ang-(3−4)], an Ang II-derived dipeptide, overcomes in-
hibition of plasma membrane Ca2+-ATPase promoted by nanomolar concentrations of Ang II in basolateral
membranes of renal proximal tubule cells, with involvement of a so far unknown AT2R-dependent and NO-
independent mechanism. The present study investigates the signaling pathway triggered by Ang-(3−4)
that is responsible for counteracting the inhibitory effect of Ang II, and attempts to elucidate the functional
interaction of the dipeptide with Ang II at the level of AT2R. Stimulation by cholera toxin of Gsα protein struc-
turally linked to AT2R − as revealed by their co-immunoprecipitation − mimicked the effect of Ang-(3−4)
on Ca2+-ATPase activity. Furthermore, addition of dibutyril-cAMP (db-cAMP) mimicked Ang-(3−4), where-
as the speciﬁc PKA inhibitor, PKAi(5–24) peptide, suppressed the counter-regulatory effect of Ang-(3−4) and
the AT2R agonist, CGP42112A. Membrane-associated PKA activity was stimulated by Ang-(3−4) or
CGP42112A to comparable levels as db-cAMP, and the Ang-(3–4) effect was abrogated by the AT2R antago-
nist PD123319, whereas the AT1R antagonist Losartan had no effect. Ang-(3−4) stimulated PKA-mediated
phosphorylation of Ca2+-ATPase and activated PKA to comparable levels. Binding assays demonstrated
that Ang-(3−4) could not displace 3H-Ang II from HEK 293T cells expressing AT2R, but 10−10 mol/L Ang-
(3−4) resulted in the appearance of a probable higher-afﬁnity site (picomolar range) for Ang II. The results
presented herein demonstrate that Ang-(3−4), acting as an allosteric enhancer, suppresses Ang II-mediated
inhibition of Ca2+-ATPase through an AT2R/cAMP/PKA pathway, after inducing conformational changes in
AT2R that results in generation of higher-afﬁnity sites for Ang II.
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Recently, new components of the renin angiotensin system (RAS)
have been described including bioactive shorter peptides derived
from Angiotensin II (Ang II), such as Ang III, Ang IV and Ang-(1−7)
(for review, see [1]). These metabolites exert their effects by inter-
acting with the classic receptors described for Ang II, the AT1 and
AT2 receptors (AT1R and AT2R), or acting through their own recep-
tors, e.g. AT4R and AT(1−7)R (MAS), which are speciﬁc for Ang IV
and Ang-(1−7), respectively [2,3]. Actions that are similar or oppo-
site to those generated upon binding of Ang II to its receptors can
be observed, depending on the type of receptor being activated.
Recently, we found parallel pathways in the renal cortex that can
generate a very short, potent Ang II-derived metabolite, Ang-(3−4) [4].
Importantly, this Ang II-derived peptide displays antihypertensive ac-
tions in vivo and in vitro [5,6]. Furthermore, we demonstrated [7] that
Ang-(3−4) counteracts – with femtomolar afﬁnity – the inhibition that
10−10 mol/L Ang II promotes− via PKC− on Ca2+-ATPase resident in
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ATPase is responsible for the ﬁne tuning of cytosolic Ca2+, and proximal
reabsorption of ﬂuid is modulated by the intracellular activity of this
cation [9], the inﬂuence of Ang-(3−4) on transepithelial Ca2+ ﬂuxes
emerges as a novel physiological process for controlling the volume of
body ﬂuid compartments, and consequently, of arterial pressure. To
date, the signaling cascade triggered by this potent dipeptide remains
unknown.
We have demonstrated that cAMP-dependent protein kinase
(PKA) activates the plasma membrane Ca2+-ATPase in proximal tu-
bules [10]. PKA activation antagonized the inﬂuence of PKC on renal
(Na++K+)ATPase [11] and the recently cloned and puriﬁed [12]
ouabain-insensitive Na+-ATPase [13] through interacting with path-
ways that involve Ang II receptors. Therefore, we hypothesized that
Ang-(3−4)-induced reactivation of the Ang II-inhibited renal Ca2+-
ATPase involves triggering of the PKA-signaling pathways in proximal
tubule cells.
The present work investigated whether Ang-(3−4) modiﬁes Ang II
binding at the level of AT2R in a renal cell line that only expresses this
class of receptors, and if a PKA pathway downstream of AT2R and
PKA-mediated phosphorylation of renal Ca2+-ATPase is associated
with reactivation of the renal Ca2+-ATPase that is inhibited by physio-
logical Ang II concentrations.
2. Experimental procedures
2.1. Animal care
Santa Inês sheep were raised on ranches in Jequié (BA, Brazil) and
Montes Claros (MG, Brazil) that are under supervision of the Brazilian
Ministry of Agriculture. The health of the animals was certiﬁed by a
licensed veterinarian from an authorized slaughterhouse. Sheep
were used due to the fact that their kidneys produce abundant levels
of Ca2+-ATPase and because their kidneys are frequently discarded as
wastage. This avoids use of experimental animals such as rats, which
would be sacriﬁced for their kidneys only. This study was approved
by the local ethics committee for the use of animals in biomedical
assays (IBCCF No.104), which follows the recommendations of the
National Institute of Health (NIH) guide for the care and use of labo-
ratory animals.
2.2. Materials
Human embryonic kidney cells (HEK 293T) were purchased from
American Type Culture Collection.
3
H-Ang II was obtained from GE
Healthcare. Unlabeled Ang II, the AT2R agonist CGP42112A, cholera
toxin (CTX), dibutyril cyclic AMP (db-cAMP), histone H8 and the AT2R
antagonist PD123319 were bought from Sigma-Aldrich; the PKA inhib-
itor peptide (PKAi) was purchased from Calbiochem. Ang-(3−4) was
synthesized by EZBiolab. Losartan was from Merck, Sharp & Dohme,
and Protein A/G PLUS-agarose from Santa Cruz Biotechnology. The
5f10 antibody and phospho-(Ser/Thr) PKA substrate antibodies were
purchased from Thermo Scientiﬁc and Cell Signaling Inc., respectively.
The anti-AT2R (anti-goat and anti-rabbit) and anti-Gsα protein anti-
bodies were obtained from Santa Cruz Biotechnology and Calbiochem,
respectively.
32
P-labeled orthophosphate (
32
Pi) was purchased from the
Brazilian Institute of Energy and Nuclear Research, and used to prepare
[γ-
32
P]ATP according toMaia and coworkers [14]. The radioactivity recov-
ered in assays was quantiﬁed using a liquid scintillation counter.
2.3. Cell culture and transfections
HEK 293T cells were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM) (Invitrogen) supplemented with 10% fetal bovine
serum, gentamycin sulfate (50 μg/ml) and glutamine (2 mmol/L) in
a 5% CO2/air atmosphere. Transient transfections of the cells wereperformed using the calcium phosphate precipitation method de-
scribed by Gether and coworkers [15].
2.4. Binding assays
HEK 293T cells transfected with the AT2R expression plasmid were
transferred to 12-well culture plates (3×105 cells/well) 24 h before
binding assays were carried out. One day after plating, cells were
washed brieﬂywith cold 25 mmol/L Tris–HCl buffer (pH7.4) containing
140 mmol/L NaCl, 5 mmol/L MgCl2 and 0.1% bovine serum albumin
(BSA). Binding experiments were performed at 4 °C, and initiated by
adding 4×10−12 mol/L
30
H-Ang II and increasing concentrations
(10−11 to 10−6 mol/L) of non-radioactive Ang II or Ang-(3−4) as com-
petitors. In one series of experiments, bindingwas initiatedwith
3
H-Ang
II 4×10−12 mol/L and displacement with unlabeled Ang II was assayed
in the presence of a ﬁxed Ang-(3−4) concentration (10−10 mol/L). The
binding buffer consisted of 25 mmol/L Tris–HCl (pH 7.4), 5 mmol/L
MgCl2, 0.1% BSA and 100 μg/ml bacitracin. The competition proﬁles and
IC50 values were calculated based on one- or two-site competition
proﬁle analysis tools using GraphPad Prism 4.0 software.
2.5. Preparation of basolateral membranes from kidney proximal tubule
cells
Membranes were isolated from the outer cortex (cortex corticis) of
sheep kidneys [7]. More than 90% of the cell population in this region
comprises proximal tubules [16]. The basolateral membrane-enriched
fraction was isolated and puriﬁed using the Percoll gradient method
[10,17]. Controls for enrichment with basolateral membranes and
for minimal residual contamination with other intracellular mem-
branes have been described elsewhere [17].
2.6. Plasma membrane Ca2+-ATPase activity assays
Ca2+-ATPase activity determinations and calculation of total CaCl2
needed for the required free Ca2+ concentrationwere as described pre-
viously [7]. Brieﬂy, membrane suspensions (0.2 mg/ml in 250 mmol/L
sucrose) were preincubated for 30 min at 37 °C with 1 mmol/L ouabain
and supplied with a basic reactionmedium containing (in mmol/L) bis-
TRIS-propane buffer 50 (pH 9.0), MgCl2 5, NaN3 10, KCl 120, EGTA 0.2
and CaCl2 0.27 (resulting in 20 μmol/L free Ca2+). Other additions are
indicated in the corresponding ﬁgure legends. The plasma membrane
Ca2+-ATPase activity was calculated as the difference between the ac-
tivities in the absence and presence of 2 mmol/L EGTA. The reaction
was started by adding 5 mmol/L [γ-
32
P]ATP (speciﬁc activity ~1 Ci/mol),
and after 20 min at 37 °C, it was stopped by adding 2 vol of activated
charcoal (in 0.1 mol/L HCl). The suspensions were centrifuged at
18,000×g and aliquots of the clear supernatants were counted using a
liquid scintillation counter. Speciﬁc additions of other reagents were de-
tailed in the corresponding ﬁgures or ﬁgure legends.
2.7. Determination of cAMP-dependent protein kinase activity
The PKA activity was measured through the incorporation of the
γ-phosphoryl group of [γ-
32
P]ATP into histone in the absence or pres-
ence of PKAi, a speciﬁc PKA inhibitor [10,18]. The basolateral mem-
branes (0.7 mg/ml in 0.1 ml ﬁnal volume) were added to medium
containing 20 mmol/L HEPES-TRIS (pH 7.0), 4 mmol/L MgCl2,
10 nmol/L 3-isobutyl-1-methylxanthine (IBMX) and 1.5 mg/ml his-
tone H8, with or without 100 nmol/L PKAi. Other additions are indi-
cated in the corresponding ﬁgure legends. After mixing, histone
phosphorylation was initiated through the addition of 10 μmol/L [γ-
32
P]ATP (10 Ci/mmol), carried out at 37 °C for 10 min and arrested
by adding 0.1 ml trichloroacetic acid (TCA) (40%, w/v). After vigorous
stirring, samples were ﬁltered under vacuum (Millipore ﬁlters,
0.45 μm pore diameter). The ﬁlters were washed with 8 ml 20% TCA
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32
P]
ATP, and counted using a liquid scintillation counter.
2.8. Immunoprecipitation, SDS-PAGE and immunodetection of the
AT2R/Gsα complex
Membranes (1 mg/ml) were solubilized in a sucrose solution con-
taining 0.1% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) for 30 min at room temperature. Ten micro-
liters of primary anti-goat polyclonal antibody of AT2R was mixed with
1 ml membrane suspension and incubated at 4 °C for 1 h, supplemented
with 20 μL of protein A/G PLUS-agarose and incubated overnight with
gentle stirring. The samples were centrifuged at 1000 g for 5 min and
the supernatant retained as a control for the immunoprecipitation proce-
dure. The pellet was washed three times with Tris-buffered saline (TBS)
before being heated in a water-bath to 100 °C for 4 min with 40 μL SDS-
PAGE sample buffer. After ﬁnal centrifugation at 16,100 g for 2 min, the
supernatant was subjected to SDS-PAGE followed by Western blotting.
Sample proteins were separated using SDS-PAGE (10%) and trans-
ferred to nitrocellulose membranes at 350 mA. The membranes were
incubated with 5% non-fat milk in TBS (pH 7.6) for 1 h to prevent
non-speciﬁc binding and probed with rabbit polyclonal anti-Gsα anti-
body (1:1000 dilution) for 1 h at room temperature under gentle stir-
ring, washed three times with TBS containing 0.1% Tween 20 (TBST),
exposed to the secondary antibody, washed again and visualized
using ECL™. For a control of the efﬁciency of immunoprecipitation,
AT2R was immunodetected using an anti-rabbit polyclonal antibody
(1:500) after stripping of the nitrocellulose membrane. AT2R and
Gsα have a molecular mass close to that of the heavy chain of IgG.
Therefore, the strategy was to immunoprecipitate the receptors
using an anti-goat polyclonal antibody, followed by a rabbit Gsα or
AT2R polyclonal antibody for the Western blotting, to minimize the
appearance of unspeciﬁc bands. A negative control (Western blotting
without membrane proteins) was used for precise localization of the
IgG bands.
2.9. PKA-mediated phosphorylation of Ca2+-ATPase activity
Ca2+-ATPase was phosphorylated and immunoprecipitated as fol-
lows: basolateral membranes (1 mg/ml) were incubated in a reaction
medium (ﬁnal volume 1 ml) containing 50 mmol/L bis-TRIS-propane
buffer (pH 7.4), 0.5 mmol/L ouabain, 5 mmol/L MgCl2, 10 mmol/L NaF,
CaEGTA buffer (60 μmol/L Ca2+) and 10 nmol/L IBMX, supplemented
with 10−10 mol/L Ang-(3−4), 10−7 mol/L db-cAMP and 10−7 mol/L
PKAi in the combinations detailed in the corresponding ﬁgure legend.
Phosphorylation was initiated by adding a mixture of 120 mM KCl and
5 mmol/L unlabeled ATP. After 10 min at 37 °C, the reaction was
stopped using 0.1% (w/v) CHAPS. The tubes were supplemented with
10 μL anti-Ca2+-ATPase antibody (5f10 anti-mouse antibody; 1:500 di-
lution) and incubated for 1 h at 4 °C before 20 μL A/G PLUS-agarosewas
added. The mixtures were maintained under gentle agitation at 4 °C
overnight, and centrifuged at 1000 g for 5 min at the same temperature.
The sediments were washed three times using TBS, and the ﬁnal pellets
were resuspended in 40 μL SDS-PAGE sample buffer before being heat-
ed to 100 °C for 4 min. After centrifugation at 16,100 g for 2 min, the su-
pernatant was subjected to SDS-PAGE followed by Western blotting.
Sample proteins were separated using SDS-PAGE (10%) and trans-
ferred to nitrocellulose membranes at 350 mA. The membranes were
incubated with 5% non-fat milk in TBS (pH 7.6) for 1 h to prevent
non-speciﬁc binding and probed with anti-Ca2+-ATPase antibody
5f10 (1:500 dilution) overnight at 4 °C. The nitrocellulose membranes
werewashedﬁve times for 3 min using TBSwith 0.1% Tween 20, probed
using anti-mouse secondarymonoclonal antibody (1:2500 dilution) for
1 h and developed using ECL™. The membranes were stripped using
0.2 mol/L glycine (pH 2.2) for 1 h, incubated with polyclonal anti-
rabbit phospho-(Ser/Thr) PKA substrate antibody (1:1000 dilution)and treated as above, with the exception that a secondary anti-rabbit
polyclonal antibody was used (1:5000 dilution).
2.10. Statistical analysis
The data are presented as mean±SE. Differences were analyzed
using one-way ANOVA, followed by a Newman–Keuls post test. Dif-
ferences were considered signiﬁcant at pb0.05.
3. Results
3.1. Involvement of cAMP-mediated pathway in the recovery of the Ang
II-inhibited Ca2+-ATPase activity
During experiments where single concentrations of Ang-(3–4) and
Ang II were assayed to demonstrate counteracting effects on Ca2+-
ATPase, the concentrations used were 10−14 mol/L and 10−10 mol/L,
respectively. We crossed these concentrations with dose–response cur-
ves obtained previously and demonstrated: (i) 10−14 mol/L Ang-(3–4)
completely reactivated the Ca2+-ATPase inhibited by 10−10 mol/L Ang
II [7]; and that (ii) the maximal inhibition of Ca2+-ATPase is attained
using 10−10 mol/L Ang II [8].
The experiments depicted in Fig. 1 investigated whether a cAMP-
mediated pathway is involved in maintaining normal Ca2+-ATPase ac-
tivity in the presence of an inhibitory concentration (10−10 mol/L) of
Ang II. Fig. 1A demonstrates that stimulation of the membrane-
associated adenylyl cyclase by CTX mimicked the counteracting effect
of Ang-(3−4) on the inhibition of Ca2+-ATPase by Ang II, whereas the
toxin alone had no effect. In addition, Fig. 1B demonstrates that addition
of db-cAMP abrogated the inhibition of the Ca2+ pump by Ang II, and
had no inﬂuence when used in isolation.
3.2. Gsα protein is associated with AT2R in basolateral membranes
Gs proteins are linked with stimulation of CTX-stimulated cAMP-
mediated pathways [19]. Therefore, we investigated a possible struc-
tural link between AT2R and Gs proteins in basolateral membranes
(probed against the α subunit). Fig. 2 demonstrates that Gsα protein
(A) and AT2R (C) are present in basolateral membranes, and more im-
portantly, clearly demonstrates that almost all originally membra-
nous Gsα are present in immunoprecipitates obtained using the
antibody against AT2R (B). A negative control of immunoprecipita-
tion using an anti AT2R antibody without basolateral membranes,
followed by Western blotting for AT2R, allowed visualization of the
two IgG bands (heavy and light) (D), with molecular masses different
from that seen for AT2R (compare C and D).
3.3. Speciﬁc blockade of PKA impairs Ca2+-ATPase reactivation by
Ang-(3−4) or by the AT2R agonist CGP42112A
Fig. 3 demonstrates that recovery of control of Ca2+-ATPase activ-
ity by Ang-(3−4) or CGP42112A did not occur in the presence of the
speciﬁc PKA inhibitor PKAi peptide, indicating that PKA participates
downstream of AT2R in the reactivation of the Ca2+-ATPase inhibited
by 10−10 mol/L Ang II.
3.4. Ang-(3−4) stimulates the membrane-associated PKA in basolateral
membranes
The results presented in Fig. 4A demonstrate that Ang-(3−4)
stimulated the PKA that is associated to basolateral membranes of
proximal tubules [20] even in subfemtomolar concentrations; fur-
thermore, 10−14 mol/L Ang-(3−4) stimulated PKA to the same ex-
tent as that obtained with db-cAMP (Fig. 4B).
Fig. 1. Reactivation by Ang-(3−4) of the Ang II-inhibited renal Ca2+-ATPase activity. (A) Ca2+-ATPase activity was assayed as described in Experimental procedures in the presence
of Ang II, Ang-(3−4) and CTX in the combinations and concentrations shown on the abscissa. Data are mean±SE (n=7). (B) Ca2+-ATPase activity was assayed in the presence of
Ang II and dibutyryl cyclic AMP (db-cAMP) in the combinations shown on the abscissa. Data are mean±SE (n=3). Different lowercase letters above bars indicate statistically dif-
ferent mean values (pb0.05).
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reactivates Ca2+-ATPase in basolateral membranes
Additional evidence concerning the participation of AT2R in reac-
tivation by Ang-(3−4) of the Ang II-inhibited Ca2+-ATPase via PKA is
presented in Fig. 5A. First, the AT2R antagonist PD123319 blocked stim-
ulation of membrane-associated PKA activity by Ang-(3−4); second,
the AT2R agonist CGP42112A reproduced the effect of Ang-(3−4). Fur-
thermore, losartan (a selective AT1R antagonist) was unable to abolish
activation of the kinase by the dipeptide (Fig. 5B).Fig. 2. Gsα protein is associated with AT2R in the basolateral membranes of proximal
tubule cells. Immunoprecipitation, SDS-PAGE and immunodetection were carried out
as described in Experimental procedures. Representative immunodetections of 3 per-
formed with different membrane preparations in the conditions described as follows.
(A) Western blotting analysis in basolateral membranes (BLM) demonstrate the pres-
ence of Gsα (40–43 kDa). The gel was loaded with the amounts of membrane protein
shown. (B) Western blotting of Gsα (40–43 kDa) using a rabbit polyclonal antibody
after immunoprecipitation using a goat polyclonal antibody against AT2R. IP: immuno-
precipitate, S: supernatant. (C) Immunodection of AT2R (45 kDa) using a rabbit poly-
clonal antibody after immunoprecipitation of AT2R with the use of a goat polyclonal
antibody against AT2R. IP: immunoprecipitate, S: supernatant. (D) Negative control
showing that there is no AT2R band when the immunodetection procedure was carried
out in the absence of basolateral membranes. The 25 and 50 kDa bands correspond to
the IgG light and heavy chains, respectively.3.6. Ang-(3−4) stimulates phosphorylation of renal Ca2+-ATPase that is
recognized by a phospho-(Ser/Thr) PKA antibody
Fig. 6 demonstrates that Ang-(3−4) stimulates basal phosphory-
lation of the Ca2+-ATPase recognized by a speciﬁc antibody against
small amino acid sequences in proteins phosphorylated by PKA. This
hyperphosphorylation obtained with Ang-(3–4) is comparable to
that observed in the presence of db-cAMP, and the increase in phos-
phorylation correlates with the stimulus of PKA activity in vitro
(Fig. 4B). When PKAi is added, the effect of Ang-(3−4) on Ca2+-
ATPase phosphorylation is almost completely abrogated.
3.7. Binding of Ang-(3−4) to the AT2R generates a probable
higher-afﬁnity site for Ang II
Despite the aforementioned evidence that Ang-(3−4) exerts its
effects via AT2R, the peptide could not displace
3
H-Ang II over a
wide range of concentrations (Fig. 7A, □) in HEK 293T cells express-
ing AT2R. Unlabeled Ang II exhibited a competition proﬁle where
the following equation was adjusted to the experimental points (■):
%3 H−Ang II bound ¼ bottomþ top – bottomð Þ= 1þ 10X− log IC50
 n o
ð1ÞFig. 3. The speciﬁc PKA inhibitor, PKAi peptide, suppresses the reactivating effect of Ang-
(3−4) and the AT2R agonist, CGP42112A, on the Ca2+-ATPase inhibited by Ang II. Assays
were carried out in the presence of Ang II, Ang-(3−4), PKAi and CGP42112A, in the com-
binations shown on the abscissa. Data are mean±SE (n=6). Different lowercase letters
above bars indicate statistically different mean values (pb0.05).
Fig. 4. Ang-(3−4) stimulates the membrane-associated PKA. PKA activity in basolateral membranes was assayed in the presence of the Ang-(3−4) (A) and db-cAMP concentrations
(B) shown on the abscissae. Different lowercase letters above bars indicate statistically different mean values (pb0.05). Data are mean±SE (n=7 and n=5 in A and B,
respectively).
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the curve, “X” is the logarithm of the concentration of unlabeled
Ang II, and “IC50” is the concentration of unlabeled Ang II that is ef-
fective for displacing 50% of the
3
H-Ang II initially bound.
When competition binding assays for Ang II were performed in the
presence of a constant concentration (10−10 mol/L) of Ang-(3−4), we
observed the appearance of a probable higher-afﬁnity site for Ang II,
with an IC50 approximately four orders of magnitude lower than in
the absence of Ang-(3−4) (Fig. 7B). In this case, the competition proﬁle
was obtained using an equation derived for two classes of sites:
%3H−Ang II bound ¼ bottomþ top – bottomð Þ
×

Fraction 1= 1þ 10X – log IC50 of fraction 1
 h i
þ 1 – Fraction 1ð Þ= 1þ 10X – log IC50 of fraction 2
 h i
ð2Þ
where “bottom”, “top” and “X” have the deﬁnitions outlined above.
“Fraction 1” corresponds to parcel of receptors with high afﬁnity for
Ang II, and “Fraction 2” corresponds to receptors (sites) with lower af-
ﬁnity for Ang II. The IC50 values for these two classes of sites are repre-
sented by Eq. (2).
The binding afﬁnity data calculated from these equations are pres-
ented in Table 1.
4. Discussion
Signaling pathways coupled to AT1R receptors are relatively well
documented, whereas those linked to AT2R remain poorly understoodFig. 5. PKA is functionally linked to AT2R in basolateral membranes. (A) PKA activity in ba
PD123319, and the AT2R agonist, CGP42112A, in the combinations shown. Data are mean±
nations shown. Assays were performed in the presence of Ang-(3−4) and losartan in the co
ters above bars indicate statistically different mean values (pb0.05).[21,22]. Herein, we present evidence that Ang-(3−4), in addition to
its reported inhibition of the angiotensin converting enzyme (ACE)
[5,23–25], can interact with AT2R coupled to Gs proteins in the
basolateral membranes of kidney proximal tubule cells. From a phys-
iological point of view, the concentrations of Ang-(3−4) used during
the present study are less than those present in human plasma and
renal tissue, where the dipeptide can accumulate [26,27]. Down-
stream adenylyl cyclase and PKA activation occurs after interaction
of Ang-(3−4) with AT2R/Gs and culminates in the reactivation of the
neighboring plasma membrane Ca2+-ATPase inhibited by picomolar
Ang II concentrations. Most important in terms of direct evidence con-
cerning the interaction of Ang-(3−4) with the membrane-associated
PKA is the stimulation – not previously described – of the kinase by
subfemtomolar Ang-(3−4) concentrations (see Fig. 4). The results
presented in Fig. 6 demonstrating stimulation of the regulatory phos-
phorylation of Ca2+-ATPase, together with those showing involvement
of AT2R, provide further evidence that Ca2+-ATPase is the ﬁnal target of
a reactivating pathway, AT2R→Gs→adenylyl cyclase→cAMP→PKA, in
which Ang-(3−4) is a primary messenger.
Isoform 1 of Ca2+-ATPase, which predominates in renal proximal
tubule cells and can be phosphorylated by PKA [10], possesses a spe-
ciﬁc site for this kinase, localized downstream of the calmodulin bind-
ing domain [28,29]. However, several isoforms of Ca2+-ATPase have a
threonine residue target for PKC in the pump sequence corresponding
to the calmodulin binding domain [29]. It may be speculated that the
inhibitory PKC-mediated phosphorylation of the latter in the pres-
ence of Ang II [8] is counteracted by the PKA-mediated stimulatory
phosphorylation of the former site elicited by Ang-(3−4) (Figs. 4B
and 6). If this were the case, opposite phosphorylations elicited
by Ang II and Ang-(3−4) could act by modulating binding of thesolateral membranes was assayed in the presence of Ang-(3−4), the AT2R antagonist,
SE (n=8). (B) PKA activity in the presence of Ang-(3−4) and losartan, in the combi-
mbinations shown. Data are mean±SE (n=5). In both panels different lowercase let-
Fig. 6. PKA-mediated phosphorylation of Ca2+-ATPase in vitro, using the combinations
of db-cAMP, Ang-(3−4) and PKA inhibitor (PKAi) presented on the abscissa. Upper
panel: phospho-immunosignal detected using the phospho-(Ser/Thr) PKA substrate
antibody. Middle panel: immunodetection of Ca2+-ATPase using the 5f10 antibody.
Lower panel: quantiﬁcation of the ratio between phospho-immunosignal and intensity
of Ca2+-ATPase immunodetection. The value obtained without additions was taken as
a reference arbitrarily ﬁxed in 1.
Fig. 7. Binding of Ang-(3−4) to AT2R generates a probable high afﬁnity site for Ang II.
Binding assays were carried out in HEK 293T cells transfected with the AT2R, as de-
scribed in Experimental procedures, using
3
H-Ang II as the radioligand. (A) Competi-
tion binding assays in the presence of the increasing concentrations of unlabeled Ang
II (■) or Ang-(3−4) (□) shown on the abscissa. (B) Competition binding assays in
the presence of increasing concentrations of unlabeled Ang II and a constant concentra-
tion of Ang-(3−4) (10−10 mol/L). Note that the presence of Ang-(3−4) generates a
probable high-afﬁnity site for Ang II in the range of 10−12 mol/L. The competition pro-
ﬁles were generated using the software Prism GraphPad by non-linear regression
equations ﬁtting for 1 (A) or 2 (B) binding sites. The dashed line in A was traced by
hand. The dotted line in B separates the populations of AT2R with different afﬁnities
for Ang II. The data points are mean±SE from 3 independent experiments performed
in duplicate (n=3).
Table 1
Competition binding assays in cells expressing the AT2R.
Peptides Ang II Ang-(3−4) Ang II+Ang-(3−4)
Cell line/receptor IC50±SE IC50±SE IC50±SE
HEK-AT2R 33.7±9.1 nmol/L NCP 2.9±0.2 pmol/L
114.0±5.2 nmol/L
Competition assays using HEK-AT2R cells were performed with
3
H-Ang II in the pres-
ence of increasing concentrations of Ang II (Fig. 7A, ■), Ang-(3−4) (Fig. 7A, □) or
Ang II plus a constant concentration of Ang-(3−4) (Fig. 7B, ■). Values are mean±SE
of 3 independent experiments performed in duplicate with cells from different cul-
tures. NCP, no competition proﬁle. The binding afﬁnity data were obtained using
Eqs. (1) and (2) (see text).
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for phosphorylating processes that was proposed several years ago
[30].
The physiological relevance of the coupled Ang-(3−4)→PKA→
Ca2+-ATPase regulatory mechanism in terms of homeostasis of liquid
compartments emerges from the fact that cytosolic Ca2+ and intracel-
lular Ca2+ sparks are ﬁnely controlled by the plasmamembrane Ca2+
pump [30–33], and these oscillations regulate proximal ﬂuid reab-
sorption [9]. Therefore, the effect of Ang-(3−4) via AT2R→Gs→adenylyl
cyclase→PKA can be considered another pathway in the Ang II-
mediated Ca2+ signaling triggered as a result of Ang II binding to AT1R
[34], and/or from Ang II direct interaction with ACE [35].
Evidence conﬁrming the relationship between AT2R, Ang-(3−4)
and the PKA cascade in counteracting the effect of Ang II was obtained
from experiments carried out in the presence of PKAi, the speciﬁc
blocker of the α-catalytic subunit of PKA [10,18]. The inhibitor im-
pairs reactivation of the Ang II-inhibited Ca2+ pump by either Ang-
(3−4) or the AT2R agonist, CGP42112A (Fig. 3). This was supported
by the ﬁnding that the AT2R agonist stimulates PKA to a comparable
extent as cAMP and Ang-(3−4). The close structural relationship of
AT2R/Gs, demonstrated by complete coprecipitation of the Gsα pro-
tein and the receptor, could be an essential feature guaranteeing
their tight functional coupling in proximal tubule cells. AT2R and Gs
participate in downregulation of the ouabain-resistant Na+-ATPase
activity by Ang-(1−7) [13]. Therefore, diverse peptides of the RAS
family may interact to regulate active ion translocation in proximal
tubules via AT2R in addition to AT1R [9,20]. The combined targeting
of active transporters by locally-formed Ang II-derived peptide may
represent a sensitive method of ensuring a perfect paracrine adjust-
ment of ion reabsorption and ﬂuid homeostasis of body ﬂuids by
Ang II [36].
The importance of PKC and PKA-catalyzed phosphorylations in Ang
II-mediated regulatory pathways that impact ﬂuid reabsorption across
the proximal epithelium has been conﬁrmed recently through phos-
phoproteomic analysis [37]. Of note, cAMP and Ang-(3−4) reverse
the inhibition of Ca2+-ATPase by Ang II without any effect when
assayed alone, despite their stimulatory inﬂuence on the membrane-
associated PKA activity (Figs. 4 and 5) and in the phosphorylation of
the Ca2+-ATPase molecule itself (Fig. 6). Therefore, as aforementioned,
it is plausible that Ang II-triggered PKC-mediated inhibitory phosphor-
ylation activates long-range intramolecular communication [38] within
the Ca2+ pump, promoting conformational changes at sites phosphor-
ylated by PKA. As a result, interaction of the autoinhibitory domain
and catalytic domain could decrease [30] when reactivation of the
pump was physiologically required.
Finally, a pivotal question that emerges from such results concerns
the type of interaction that Ang-(3−4) plays in the Ang II-AT2R axis.
In experimental conditions where Ang-(3−4) coexists with Ang II,
there is dissociation of AT1R/AT2R heterodimers [7], and this seems
to be an obligatory requirement to overcome the doubly losartan-
and PD123329-sensitive inhibition of plasma membrane Ca2+-
ATPase promoted by 10−10 mol/L Ang II [8]. The appearance of a
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(IC50 2.9 pmol/L), i.e. four orders of magnitude higher than that ob-
served without Ang-(3–4) (IC50 33.7 nmol/L), is accompanied of a
moderate reduction in afﬁnity of the latter site to 114.0 nmol/L
(Table 1). Such alterations in afﬁnity and in the competition proﬁle
for Ang II are probably representative of a subpopulation of AT2R
with altered conformation due to the allosteric interference of Ang-
(3−4) binding, consequently responsible for complete reversing of
the Ang II-induced inhibition of the Ca2+ pump [7]. Therefore, Ang-
(3−4) would act as an allosteric modulator when bound to the
AT2R. Therefore, Ang-(3−4) would not directly compete with Ang
II, but would be responsible for inducing conformational changes in
the receptors, resulting in modiﬁcation of the Ang II binding proﬁle.
Allosteric modulators can modify afﬁnity of the primary agonist for
G protein-coupled receptors either when in their monomeric [39] or
dimeric states [40]. Therefore, in native proximal tubule membranes,
a similar behavior of conformational modiﬁcation due to the allosteric
interference of Ang-(3−4) could occur with AT2R/AT1R heterodimers
[7]. We speculate that this is a key event linked to the counter-
regulatory action of Ang-(3−4). This event would correspond to
the structural modiﬁcations induced by Ang-(3−4) in receptors that
functionally couple a primed, but silent, AT2R/Gs complex linked to
a downstream PKA pathway.
5. Conclusions
In conclusion, this study has revealed new partners of AT2R in
renal cells: the components of the cAMP-stimulated kinase pathway
resident in basolateral membranes and Ang-(3−4), the latter acting
as an allosteric modulator [40]. This expands our understanding con-
cerning AT2R functionality and its association with other receptors
that participate in renal ion and ﬂuid handling.
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